220 related articles for article (PubMed ID: 36569913)
1. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
Gao L; Hong ZN; Wu L; Yang Y; Kang M
Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
[TBL] [Abstract][Full Text] [Related]
2. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
3. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
4. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
6. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
8. Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy.
Jiang D; Song Q; Tang H; Shi P; Zhang X; Liu Y; Wang H; Deng M; Huang J; Su J; Xu C; Tan L; Hou Y
Front Oncol; 2023; 13():1067897. PubMed ID: 36925921
[TBL] [Abstract][Full Text] [Related]
9.
Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
[TBL] [Abstract][Full Text] [Related]
10. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
Chen P; Wang L; Yang X; Feng J
Biomol Biomed; 2024 Jan; 24(1):159-169. PubMed ID: 37597214
[TBL] [Abstract][Full Text] [Related]
11. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
[TBL] [Abstract][Full Text] [Related]
12. Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
Hong ZN; Huang Z; Weng K; Lin J; Kang M
Front Immunol; 2022; 13():1036396. PubMed ID: 36311738
[TBL] [Abstract][Full Text] [Related]
13. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
[TBL] [Abstract][Full Text] [Related]
16. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
[No Abstract] [Full Text] [Related]
17. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
Front Immunol; 2022; 13():836338. PubMed ID: 35300335
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Ann Surg Oncol; 2024 Jan; 31(1):272-283. PubMed ID: 37838648
[TBL] [Abstract][Full Text] [Related]
19. A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
Wong IYH; Chung JCY; Zhang RQ; Gao X; Lam KO; Kwong DLW; Chao YK; Law SYK
Ann Surg; 2022 Nov; 276(5):784-791. PubMed ID: 35876374
[TBL] [Abstract][Full Text] [Related]
20. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Yang Y; Yi Y; Wang Z; Li S; Zhang B; Sang Z; Zhang L; Cao Q; Li B
BMC Cancer; 2024 Apr; 24(1):460. PubMed ID: 38609892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
